These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 21755401)

  • 61. The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density.
    Fitzpatrick LA; Dabrowski CE; Cicconetti G; Gordon DN; Papapoulos S; Bone HG; Bilezikian JP
    J Clin Endocrinol Metab; 2011 Aug; 96(8):2441-9. PubMed ID: 21593114
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Adherence to osteoporosis therapy after an upper extremity fracture: a pre-specified substudy of the C-STOP randomized controlled trial.
    McAlister FA; Ye C; Beaupre LA; Rowe BH; Johnson JA; Bellerose D; Hassan I; Majumdar SR
    Osteoporos Int; 2019 Jan; 30(1):127-134. PubMed ID: 30232538
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Natural history, reasons for, and impact of low/non-adherence to medications for osteoporosis in a cohort of community-dwelling older women already established on medication: a 2-year follow-up study.
    Clark EM; Gould VC; Tobias JH; Horne R
    Osteoporos Int; 2016 Feb; 27(2):579-90. PubMed ID: 26286625
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Evaluation of urinary N-telopeptide of type I collagen measurements in the management of osteoporosis in clinical practice.
    Baxter I; Rogers A; Eastell R; Peel N
    Osteoporos Int; 2013 Mar; 24(3):941-7. PubMed ID: 22872068
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.
    Black DM; Schwartz AV; Ensrud KE; Cauley JA; Levis S; Quandt SA; Satterfield S; Wallace RB; Bauer DC; Palermo L; Wehren LE; Lombardi A; Santora AC; Cummings SR;
    JAMA; 2006 Dec; 296(24):2927-38. PubMed ID: 17190893
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The effect of bisphosphosphonates on bone turnover and bone balance in postmenopausal women with osteoporosis: The T-score bone marker approach in the TRIO study.
    Gossiel F; Paggiosi MA; Naylor KE; McCloskey EV; Walsh J; Peel N; Eastell R
    Bone; 2020 Feb; 131():115158. PubMed ID: 31740343
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis.
    Ringe JD; Möller G
    Rheumatol Int; 2009 Dec; 30(2):213-21. PubMed ID: 19430791
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data.
    McClung MR; Zanchetta JR; Racewicz A; Roux C; Benhamou CL; Man Z; Eusebio RA; Beary JF; Burgio DE; Matzkin E; Boonen S; Delmas P
    Osteoporos Int; 2013 Jan; 24(1):293-9. PubMed ID: 22752050
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients.
    Kamimura M; Nakamura Y; Ikegami S; Uchiyama S; Kato H; Taguchi A
    Osteoporos Int; 2017 Feb; 28(2):559-566. PubMed ID: 27650642
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Medication-taking behaviour in Bulgarian women with postmenopausal osteoporosis treated with denosumab or monthly oral bisphosphonates.
    Petranova T; Boyanov M; Shinkov A; Petkova R; Intorcia M; Psachoulia E
    Arch Osteoporos; 2017 Dec; 13(1):1. PubMed ID: 29264666
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Comparative adherence to weekly oral and quarterly intravenous bisphosphonates among patients with limited heath literacy who sustained distal radius fractures.
    Roh YH; Noh JH; Gong HS; Baek GH
    J Bone Miner Metab; 2018 Sep; 36(5):589-595. PubMed ID: 28983705
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
    Roux C; Hofbauer LC; Ho PR; Wark JD; Zillikens MC; Fahrleitner-Pammer A; Hawkins F; Micaelo M; Minisola S; Papaioannou N; Stone M; Ferreira I; Siddhanti S; Wagman RB; Brown JP
    Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Infusion of ibandronate once every 3 months effectively decreases bone resorption markers and increases bone mineral density in Chinese postmenopausal osteoporotic women: a 1-year study.
    Li M; Xing XP; Zhang ZL; Liu JL; Zhang ZL; Liu DG; Xia WB; Meng XW
    J Bone Miner Metab; 2010 May; 28(3):299-305. PubMed ID: 19855926
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Value of a new fixed-combination pack of bisphosphonate, calcium and vitamin D in the therapy of osteoporosis: results of two quantitative patient research studies.
    Ringe JD; Fardellone P; Kruse HP; Amling M; van der Geest SA; Möller G
    Drugs Aging; 2009; 26(3):241-53. PubMed ID: 19358619
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Risk of refracture associated with compliance and persistence with bisphosphonate therapy in Taiwan.
    Soong YK; Tsai KS; Huang HY; Yang RS; Chen JF; Wu PC; Huang KE
    Osteoporos Int; 2013 Feb; 24(2):511-21. PubMed ID: 22588182
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Bisphosphonates for prevention of postmenopausal osteoporosis.
    Ravn P
    Dan Med Bull; 2002 Feb; 49(1):1-18. PubMed ID: 11894721
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Comparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis: a phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging study.
    Ste-Marie LG; Brown JP; Beary JF; Matzkin E; Darbie LM; Burgio DE; Racewicz AJ
    Clin Ther; 2009 Feb; 31(2):272-85. PubMed ID: 19302900
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Persistence with teriparatide in postmenopausal osteoporosis; impact of a patient education and follow-up program: the French experience.
    Briot K; Ravaud P; Dargent-Molina P; Zylberman M; Liu-Leage S; Roux C
    Osteoporos Int; 2009 Apr; 20(4):625-30. PubMed ID: 18661089
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Should Bone Turnover Markers Be Used Routinely to Monitor Oral Bisphosphonate Osteoporosis Therapy? Yes: Measuring Adherence and Effectiveness of Therapy Benefits Patients.
    Doshi KB; Khan LZ
    Am Fam Physician; 2023 Nov; 108(5):442-443. PubMed ID: 37983691
    [No Abstract]   [Full Text] [Related]  

  • 80. Monitoring of bone turnover markers does not improve persistence with ibandronate treatment.
    Roux C; Giraudeau B; Rouanet S; Dubourg G; Perrodeau E; Ravaud P
    Joint Bone Spine; 2012 Jul; 79(4):389-92. PubMed ID: 21703900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.